|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
Dallas, Texas 75201, US
|
|
COVAXX, a division of United Biomedical, is responding to the COVID-19 breakout in a manner that is consistent with our values by following the science and putting diagnostics and solutions-thinking at the center of our approach. Our priority is to stay on the front lines to safeguard the health and well-being of our communities.
We have already deployed our antibody tests in several states in the U.S., China, and Taiwan. We are a high throughput antibody test and are actively working with communities and institutions to help detect and contain community spread.
In addition, COVAXX is developing the first Multitope Peptide-Based Vaccine that has shown promising efficacy in animals and is based on a commercially proven, safe and scalable vaccine platform. We are entering human trials later this summer.
Our mission and vision is to save and safeguard lives by tackling the global COVID-19 pandemic using cost-effective, scalable, and proven science-based solutions delivered to the world.
|
Vaxxinity Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Vaxxinity email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Vaxxinity customer service number in your country click here to find.
Jaime T is the CEO of Vaxxinity. To contact Jaime T email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.